<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased intake of L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi>, a cofactor in cellular energy metabolism, is recommended for diabetic patients with late complications </plain></SENT>
<SENT sid="1" pm="."><plain>However, its clinical benefits remain controversial </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that patients with low L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> levels would have an increased rate of <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>To test this hypothesis, we evaluated the relationship of L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> concentrations in blood with the prevalence and severity of late <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> in type 1 and 2 diabetic patients </plain></SENT>
<SENT sid="4" pm="."><plain>Human blood samples were collected from 93 and 87 patients diagnosed as having type 1 or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively, and 122 nondiabetic individuals </plain></SENT>
<SENT sid="5" pm="."><plain>The determination of free L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> concentrations in whole blood lysates was performed using ultra-performance liquid chromatography with tandem mass spectrometry </plain></SENT>
<SENT sid="6" pm="."><plain>In diabetic patients, <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> such as <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, or <z:hpo ids='HP_0000822'>hypertension</z:hpo> were recorded </plain></SENT>
<SENT sid="7" pm="."><plain>The average L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> concentration in the blood of control subjects was 33 ± 8 nmol/mL, which was not significantly different from subgroups of patients with type 1 (32 ± 10 nmol/mL) or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (36 ± 11 nmol/mL) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with low (&lt;20 nmol/mL) l-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> levels did not have increased occurrences of late <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, patient subgroups with higher L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> concentrations did not have decreased prevalence of late <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our results provide evidence that higher L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> concentrations do not prevent late <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> in type 1 and 2 diabetic patients </plain></SENT>
</text></document>